CHINARES PHARMA Keeps Share Base Unchanged at 6.28 Billion in March 2026, Confirms Public Float Compliance

Bulletin Express04-01

China Resources Pharmaceutical Group Limited (CHINARES PHARMA) filed its Monthly Return for the period ended 31 March 2026, showing no movements in share capital during the month.

• Issued Shares: The company closed March with 6.28 billion ordinary shares in issue, identical to the level at the end of February. No treasury shares were held or created.

• Public Float: Management confirmed compliance with the Hong Kong Stock Exchange’s 25 percent minimum public float requirement.

• Share Option Scheme: – Outstanding options: 0 – Remaining option pool: 628.45 million shares available for future grants under the scheme approved on 12 December 2017. – No new shares were issued and no treasury shares were transferred during the month.

• Capital Instruments: The filing recorded no warrants, convertible securities, or other agreements that could affect share capital, and no repurchases or cancellations occurred.

Overall, CHINARES PHARMA’s equity structure remained stable in March, with sufficient headroom preserved under its existing share option mandate and full adherence to listing rules on public float.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1154391152?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 17:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154391152","market":"hk","top_or_hot":-1,"title":"CHINARES PHARMA Keeps Share Base Unchanged at 6.28 Billion in March 2026, Confirms Public Float Compliance","media":"Bulletin Express","content":"<p>China Resources Pharmaceutical Group Limited (CHINARES PHARMA) filed its Monthly Return for the period ended 31 March 2026, showing no movements in share capital during the month.</p>\n<p>• Issued Shares: The company closed March with 6.28 billion ordinary shares in issue, identical to the level at the end of February. No treasury shares were held or created.</p>\n<p>• Public Float: Management confirmed compliance with the Hong Kong Stock Exchange’s 25 percent minimum public float requirement.</p>\n<p>• Share Option Scheme:  \n  – Outstanding options: 0  \n  – Remaining option pool: 628.45 million shares available for future grants under the scheme approved on 12 December 2017.  \n  – No new shares were issued and no treasury shares were transferred during the month.</p>\n<p>• Capital Instruments: The filing recorded no warrants, convertible securities, or other agreements that could affect share capital, and no repurchases or cancellations occurred.</p>\n<p>Overall, CHINARES PHARMA’s equity structure remained stable in March, with sufficient headroom preserved under its existing share option mandate and full adherence to listing rules on public float.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CHINARES PHARMA Keeps Share Base Unchanged at 6.28 Billion in March 2026, Confirms Public Float Compliance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCHINARES PHARMA Keeps Share Base Unchanged at 6.28 Billion in March 2026, Confirms Public Float Compliance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-01 17:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Resources Pharmaceutical Group Limited (CHINARES PHARMA) filed its Monthly Return for the period ended 31 March 2026, showing no movements in share capital during the month.</p>\n<p>• Issued Shares: The company closed March with 6.28 billion ordinary shares in issue, identical to the level at the end of February. No treasury shares were held or created.</p>\n<p>• Public Float: Management confirmed compliance with the Hong Kong Stock Exchange’s 25 percent minimum public float requirement.</p>\n<p>• Share Option Scheme:  \n  – Outstanding options: 0  \n  – Remaining option pool: 628.45 million shares available for future grants under the scheme approved on 12 December 2017.  \n  – No new shares were issued and no treasury shares were transferred during the month.</p>\n<p>• Capital Instruments: The filing recorded no warrants, convertible securities, or other agreements that could affect share capital, and no repurchases or cancellations occurred.</p>\n<p>Overall, CHINARES PHARMA’s equity structure remained stable in March, with sufficient headroom preserved under its existing share option mandate and full adherence to listing rules on public float.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"华润医药","start_time":0,"source_url":"","article_id":"1154391152","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154391152","pubTimestamp":1775035727,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China Resources Pharmaceutical Group Limited (CHINARES PHARMA) filed its Monthly Return for the period ended 31 March 2026, showing no movements in share capital during the month. • Issued Shares:...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药"},"translate_title":"CHINARES PHARMA于2026年3月将股本基数维持在62.8亿股不变，确认公众持股量合规性","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"China Resources Pharmaceutical Group Limited (CHINARES PHARMA) filed its Monthly Return for the period ended 31 March 2026, showing no movements in share capital during the month.\n• Issued Shares: The company closed March with 6.28 billion ordinary shares in issue, identical to the level at the end of February. No treasury shares were held or created.\n• Public Float: Management confirmed compliance with the Hong Kong Stock Exchange’s 25 percent minimum public float requirement.\n• Share Option Scheme:  \n  – Outstanding options: 0  \n  – Remaining option pool: 628.45 million shares available for future grants under the scheme approved on 12 December 2017.  \n  – No new shares were issued and no treasury shares were transferred during the month.\n• Capital Instruments: The filing recorded no warrants, convertible securities, or other agreements that could affect share capital, and no repurchases or cancellations occurred.\nOverall, CHINARES PHARMA’s equity structure remained stable in March, with sufficient headroom preserved under its existing share option mandate and full adherence to listing rules on public float.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1154391152","isCrawlerRequest":true}